Detalhe da pesquisa
1.
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study.
Haematologica
; 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38356463
2.
Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma.
Ann Hematol
; 100(7): 1769-1778, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33885924
3.
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma.
Clin Cancer Res
; 30(10): 2085-2096, 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38466644
4.
Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM).
Leuk Lymphoma
; 63(14): 3438-3447, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36124538
5.
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma.
Blood Cancer J
; 12(4): 68, 2022 04 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35440057
6.
Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma.
Hemasphere
; 4(3): e380, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32647799
7.
Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation.
Semin Hematol
; 55(4): 189-196, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30502846